PTC Therapeutics traded at $53.27 this Monday August 8th, decreasing $0.23 or 0.43 percent since the previous trading session. Looking back, over the last four weeks, PTC Therapeutics lost 24.14 percent. Over the last 12 months, its price rose by 33.44 percent. Looking ahead, we forecast PTC Therapeutics to be priced at 52.02 by the end of this quarter and at 47.81 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
53.27
Daily Change
-0.43%
Yearly
33.44%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 3,643.00 179.00 5.17% 74.06%
Acadia Pharmaceuticals 16.78 0.34 2.07% -12.51%
Alnylam Pharmaceuticals 218.58 -5.47 -2.44% 11.96%
Amgen 246.88 0.63 0.25% 7.27%
BioCryst Pharmaceuticals 14.05 0.31 2.26% -20.22%
Biogen 221.87 3.67 1.68% -34.74%
Bluebird Bio 5.59 1.01 22.05% -77.67%
BioMarin Pharmaceutical 95.82 2.84 3.05% 22.64%
Cytokinetics 51.82 5.10 10.92% 62.85%
Enanta Pharmaceuticals 71.31 0.35 0.49% 59.00%
Esperion Therapeutics 6.16 0.06 0.98% -56.65%
Gilead Sciences 61.50 0.41 0.67% -10.17%
Intercept Pharmaceuticals 16.27 -0.15 -0.91% -2.11%
Incyte Corp 73.25 1.09 1.51% -4.00%
Ionis Pharmaceuticals 45.78 0.08 0.17% 17.98%
Ironwood Pharmaceuticals 11.85 -0.03 -0.21% -11.27%
Karyopharm Therapeutics 4.67 -0.02 -0.32% -15.49%
Novartis 82.29 0.24 0.29% -2.79%
Puma Biotechnology 3.99 0.15 3.91% -43.80%
Pfizer 49.40 0.13 0.26% 9.61%
PTC Therapeutics 53.27 -0.23 -0.43% 33.44%
Ultragenyx Pharmaceutical 54.93 -0.67 -1.21% -37.93%
Roche Holding 315.55 -1.15 -0.36% -12.92%
Sangamo BioSciences 5.33 0.13 2.40% -45.44%
Sarepta Therapeutics 108.04 2.02 1.91% 35.39%
TG Therapeutics 7.11 0.88 14.13% -69.77%
Vertex Pharmaceuticals 291.80 3.77 1.31% 45.61%
Xencor 29.34 -0.33 -1.11% -6.02%

Indexes Price Day Year
USND 12831 173.89 1.37% -13.65%
US2000 1954 31.87 1.66% -12.58%

PTC Therapeutics
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).